The Lancet· Amit Goel, Sumit Rungta, Vinod Kumar, Shalimar, Ajay Kumar, Harshita Katiyar, Surender Singh, Amar Deep, Ajay Kumar Mishra, Ashish Awasthi, Vikasendu Agarwal, Anurag Kumar Tiwari, Dawesh Prakash Yadav, Sunit Kumar Shukla, Ujjwal Sonika, Radha Krishan Dhiman, Bharat Bhushan Rewari, Rakesh Aggarwal·· 1 天前精选评分62
sofosbuvir-velpatasvir 8周与12周方案治疗初治非肝硬化慢性丙型肝炎的非劣效性试验
[Articles] 8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India
导读
RESOLVE试验显示，对于无肝硬化的慢性HCV感染者，sofosbuvir-velpatasvir 8周方案与标准12周治疗的疗效相似。
来源：The Lancet · thelancet.com